ORLANDO-Concurrent chemoradiotherapy (CRT) is considered standard treatment for unresectable advanced head and neck cancer. A new study presented at the 2009 meeting of the American Society of Clinical Oncology (ASCO) suggests that induction chemotherapy (IC) delivered before CRT significantly improved time to treatment failure (TTF) compared with standard upfront CRT alone in this setting.
Explore this issue:August 2009
Induction chemotherapy prior to CRT is feasible and achievable. The sequential strategy doubles TTF and achieves a significant benefit in locoregional control. Induction chemotherapy should be considered the new standard of care, said Ricardo Hitt, MD, of the University Hospital 12 de Octubre in Madrid.
Although this presentation was selected for inclusion in the Best of ASCO program (an educational initiative that highlights important presentations from the ASCO annual meeting), the formal discussant of the trial took issue with aspects of the design and told listeners that more research is needed before induction chemotherapy can be considered a standard.